The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Mapping The Neural Circuits Involved In Appetite And Feeding Behaviour
Funder
National Health and Medical Research Council
Funding Amount
$404,892.00
Summary
My research project involves deconstructing the neural circuitry underlying feeding behaviour using innovative genetically-based methods. I aim to identify and characterise the major projections of the oxytocin-expressing neurons in the paraventricular hypothalamic nucleus, which have recently been identified as critical in the feeding neurocircuitry. This emerging field of research is predicted to transform our understanding and treatment of disorders such as obesity and anorexia nervosa.
Preclinical Assessment Of The Potential Utility Of Oxytocin And A Novel Oxytocin Agonist For The Treatment Of Substance Use Disorders And Social Dysfunction
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
Recent work has highlighted the utility of stimulating the brain oxytocin (OT) system in the treatment of numerous psychiatric disorders, in particular substance use disorders and social disorders (e.g. autism). I will focus on the continuation of two interrelated projects during my Fellowship: (1) preclinical exploration of OT as a novel treatment for alcohol use disorders; and (2) further developing our novel non-peptide OT agonist (SOC-1), which has profound pro-social effects.